{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:40:06Z","timestamp":1794408006799,"version":"4.9.0"},"reference-count":38,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1136\/jnnp-2017-315603","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:40:33Z","timestamp":1496364033000},"page":"639-647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":147,"title":["Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response"],"prefix":"10.1136","volume":"88","author":[{"given":"Jan-Patrick","family":"Stellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Krumbholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gahlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Borisow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Pache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Havla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Geis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Angstwurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Lea","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Zeltner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf Andreas","family":"Linker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Marziniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Then Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Hofstadt-van Oy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Faiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Trebst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"key-10.1136\/jnnp-2017-315603-1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"key-10.1136\/jnnp-2017-315603-2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"key":"key-10.1136\/jnnp-2017-315603-3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-315603-4","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2017-315603-5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"8","key":"key-10.1136\/jnnp-2017-315603-6","first-page":"00","article-title":"Predictors of recurrence following an initial episode of transverse myelitis","volume":"1","author":"Kimbrough","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"key-10.1136\/jnnp-2017-315603-7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United\u00a0Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"key-10.1136\/jnnp-2017-315603-8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"key-10.1136\/jnnp-2017-315603-12","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in Neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","article-title":"The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in western China","volume":"39","author":"Chen","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"key-10.1136\/jnnp-2017-315603-14","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-315603-15","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-315603-16","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1474-4422(13)70089-9","article-title":"Hope for a rare disease: eculizumab in neuromyelitis optica","volume":"12","author":"Paul","year":"2013","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in Neuromyelitis optica-Ethical and design considerations","volume":"22","author":"Cree","year":"2016","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-315603-22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-315603-24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-315603-25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-315603-26","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00115-010-3192-4","article-title":"Diagnostik und Therapie der Neuromyelitis Optica: Konsensusempfehlungen der Neuromyelitis Optica Studiengruppe","volume":"82","author":"Trebst","year":"2011","journal-title":"Nervenarzt"},{"key":"key-10.1136\/jnnp-2017-315603-27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"key-10.1136\/jnnp-2017-315603-28","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-315603-29","unstructured":"Therneau TM . A package for survival analysis in S. 2015."},{"key":"key-10.1136\/jnnp-2017-315603-30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"key-10.1136\/jnnp-2017-315603-32","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2017-315603-34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis\u00a0optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"key-10.1136\/jnnp-2017-315603-35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"key-10.1136\/jnnp-2017-315603-36","first-page":"00","article-title":"Predictors of response to first-line immunosuppressive therapy in Neuromyelitis optica spectrum disorders","volume":"88","author":"Kim","year":"2017","journal-title":"Multi Scler"},{"key":"key-10.1136\/jnnp-2017-315603-37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1352458512451659","article-title":"Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies","volume":"19","author":"Chang","year":"2013","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2017-315603-38","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol - Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-315603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:07:39Z","timestamp":1601057259000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-315603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,7,13]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/jnnp-2017-315603"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-315603","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}